Published in Antimicrob Agents Chemother on September 28, 2009
VNI cures acute and chronic experimental Chagas disease. J Infect Dis (2013) 1.34
Recent advances in the treatment of mucormycosis. Curr Infect Dis Rep (2010) 1.31
In vitro and in vivo activities of posaconazole and amphotericin B in a murine invasive infection by Mucor circinelloides: poor efficacy of posaconazole. Antimicrob Agents Chemother (2012) 0.95
Rapidly progressive cutaneous Rhizopus microsporus infection presenting as Fournier's gangrene in a patient with acute myelogenous leukemia. Transpl Infect Dis (2011) 0.87
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. Antimicrob Agents Chemother (2010) 0.87
Evaluation of the efficacies of Amphotericin B, Posaconazole, Voriconazole, and Anidulafungin in a murine disseminated infection by the emerging opportunistic Fungus Sarocladium (Acremonium) kiliense. Antimicrob Agents Chemother (2013) 0.87
Multicenter evaluation of MIC distributions for epidemiologic cutoff value definition to detect amphotericin B, posaconazole, and itraconazole resistance among the most clinically relevant species of Mucorales. Antimicrob Agents Chemother (2015) 0.86
Comparative pharmacodynamics of posaconazole in neutropenic murine models of invasive pulmonary aspergillosis and mucormycosis. Antimicrob Agents Chemother (2014) 0.84
In vitro activity and in vivo efficacy of anidulafungin in murine infections by Aspergillus flavus. Antimicrob Agents Chemother (2010) 0.83
Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome. Eur J Clin Pharmacol (2012) 0.79
Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis (2009) 3.77
Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis (2006) 3.57
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother (2008) 2.70
Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother (2006) 2.65
Zygomycosis: the re-emerging fungal infection. Eur J Clin Microbiol Infect Dis (2006) 2.17
Activity of posaconazole in treatment of experimental disseminated zygomycosis. Antimicrob Agents Chemother (2003) 2.09
Comparison of a new triazole antifungal agent, Schering 56592, with itraconazole and amphotericin B for treatment of histoplasmosis in immunocompetent mice. Antimicrob Agents Chemother (1999) 2.06
Spectrum of zygomycete species identified in clinically significant specimens in the United States. J Clin Microbiol (2009) 2.02
Treatment of zygomycosis: current and new options. J Antimicrob Chemother (2008) 1.86
In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. Antimicrob Agents Chemother (2007) 1.85
Mucormycosis (zygomycosis) in a heart-kidney transplant recipient: recovery after posaconazole therapy. Clin Infect Dis (2003) 1.31
Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers. Antimicrob Agents Chemother (2009) 1.28
Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother (2005) 1.20
Posaconazole combined with amphotericin B, an effective therapy for a murine disseminated infection caused by Rhizopus oryzae. Antimicrob Agents Chemother (2008) 1.18
Posaconazole mono- or combination therapy for treatment of murine zygomycosis. Antimicrob Agents Chemother (2008) 1.15
Posaconazole concentrations in the central nervous system. J Antimicrob Chemother (2008) 1.06
Effects of double and triple combinations of antifungal drugs in a murine model of disseminated infection by Scedosporium prolificans. Antimicrob Agents Chemother (2009) 1.05
Posaconazole: a new oral antifungal agent with an expanded spectrum of activity. Am J Health Syst Pharm (2009) 1.05
Disseminated Rhizopus microsporus infection in a patient on oral corticosteroid treatment: a case report. Neth J Med (2009) 0.93
Evaluation of disk diffusion and Etest compared to broth microdilution for antifungal susceptibility testing of posaconazole against clinical isolates of filamentous fungi. J Clin Microbiol (2007) 0.87
Posaconazole as first line treatment for disseminated zygomycosis. Mycoses (2008) 0.84
Antifungal activities of posaconazole and granulocyte-macrophage colony-stimulating factor ex vivo and in mice with disseminated infection due to Scedosporium prolificans. Antimicrob Agents Chemother (2004) 0.83
Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet (2005) 8.45
Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J Clin Microbiol (2004) 4.70
Biomechanical remodeling of the microenvironment by stromal caveolin-1 favors tumor invasion and metastasis. Cell (2011) 3.37
Necrotizing cutaneous mucormycosis after a tornado in Joplin, Missouri, in 2011. N Engl J Med (2012) 3.26
Mitochondrial and nuclear DNA matching shapes metabolism and healthy ageing. Nature (2016) 2.98
Melanized fungi in human disease. Clin Microbiol Rev (2010) 2.89
Molecular phylogeny of the Pseudallescheria boydii species complex: proposal of two new species. J Clin Microbiol (2005) 2.83
Disseminated phaeohyphomycosis: review of an emerging mycosis. Clin Infect Dis (2002) 2.70
Infections caused by Scedosporium spp. Clin Microbiol Rev (2008) 2.69
Primary central nervous system phaeohyphomycosis: a review of 101 cases. Clin Infect Dis (2003) 2.62
Sporothrix brasiliensis, S. globosa, and S. mexicana, three new Sporothrix species of clinical interest. J Clin Microbiol (2007) 2.57
Phenotypic and molecular characterization of Candida nivariensis sp. nov., a possible new opportunistic fungus. J Clin Microbiol (2005) 2.52
Sequence-based identification of filamentous basidiomycetous fungi from clinical specimens: a cautionary note. J Clin Microbiol (2009) 2.44
Supercomplex assembly determines electron flux in the mitochondrial electron transport chain. Science (2013) 2.24
Molecular phylogenetic diversity, multilocus haplotype nomenclature, and in vitro antifungal resistance within the Fusarium solani species complex. J Clin Microbiol (2008) 2.16
Phylogenetic diversity and microsphere array-based genotyping of human pathogenic Fusaria, including isolates from the multistate contact lens-associated U.S. keratitis outbreaks of 2005 and 2006. J Clin Microbiol (2007) 2.02
Members of the Fusarium solani species complex that cause infections in both humans and plants are common in the environment. J Clin Microbiol (2006) 1.99
Species of Phaeoacremonium associated with infections in humans and environmental reservoirs in infected woody plants. J Clin Microbiol (2005) 1.98
In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. Antimicrob Agents Chemother (2007) 1.85
Cyclostreptin binds covalently to microtubule pores and lumenal taxoid binding sites. Nat Chem Biol (2007) 1.83
NDUFA4 is a subunit of complex IV of the mammalian electron transport chain. Cell Metab (2012) 1.82
Protein A-mediated multicellular behavior in Staphylococcus aureus. J Bacteriol (2008) 1.81
Development and validation of a high-performance liquid chromatography assay for voriconazole. Antimicrob Agents Chemother (2003) 1.77
Molecular phylogeny of Sporothrix schenckii. J Clin Microbiol (2006) 1.76
Antifungal susceptibilities of the species of the Pseudallescheria boydii complex. Antimicrob Agents Chemother (2006) 1.74
Fusarium oxysporum as a multihost model for the genetic dissection of fungal virulence in plants and mammals. Infect Immun (2004) 1.67
Molecular and phenotypic data supporting distinct species statuses for Scedosporium apiospermum and Pseudallescheria boydii and the proposed new species Scedosporium dehoogii. J Clin Microbiol (2007) 1.66
Disseminated Geosmithia argillacea infection in a German shepherd dog. Med Mycol (2009) 1.62
Epidemiology and outcome of Scedosporium prolificans infection, a review of 162 cases. Med Mycol (2009) 1.61
In vitro antifungal susceptibilities of five species of sporothrix. Antimicrob Agents Chemother (2007) 1.60
Pseudallescheria boydii (Anamorph Scedosporium apiospermum). Infection in solid organ transplant recipients in a tertiary medical center and review of the literature. Medicine (Baltimore) (2002) 1.53
Internet-accessible DNA sequence database for identifying fusaria from human and animal infections. J Clin Microbiol (2010) 1.51
Molecular identification and in vitro response to antifungal drugs of clinical isolates of Exserohilum. Antimicrob Agents Chemother (2012) 1.51
A two-locus DNA sequence database for typing plant and human pathogens within the Fusarium oxysporum species complex. Fungal Genet Biol (2009) 1.41
Molecular phylogenetic diversity of the emerging mucoralean fungus Apophysomyces: proposal of three new species. Rev Iberoam Micol (2010) 1.40
Geosmithia argillacea: an emerging cause of invasive mycosis in human chronic granulomatous disease. Clin Infect Dis (2011) 1.39
In vitro antifungal susceptibility of Cryptococcus gattii. J Clin Microbiol (2004) 1.39
Sporothrix luriei: a rare fungus from clinical origin. Med Mycol (2008) 1.38
Molecular and morphological identification of Colletotrichum species of clinical interest. J Clin Microbiol (2004) 1.35
Universal in vitro antifungal resistance of genetic clades of the Fusarium solani species complex. Antimicrob Agents Chemother (2007) 1.31
PCR protocol for specific identification of Candida nivariensis, a recently described pathogenic yeast. J Clin Microbiol (2005) 1.25
Phialosimplex, a new anamorphic genus associated with infections in dogs and having phylogenetic affinity to the Trichocomaceae. Med Mycol (2010) 1.24
Taxonomy and phylogeny of the Fusarium dimerum species group. Mycologia (2009) 1.24
Collaborative evaluation of optimal antifungal susceptibility testing conditions for dermatophytes. J Clin Microbiol (2002) 1.23
Novel multilocus sequence typing scheme reveals high genetic diversity of human pathogenic members of the Fusarium incarnatum-F. equiseti and F. chlamydosporum species complexes within the United States. J Clin Microbiol (2009) 1.22
In vitro interactions of approved and novel drugs against Paecilomyces spp. Antimicrob Agents Chemother (2004) 1.22
Sporothrix globosa, a pathogenic fungus with widespread geographical distribution. Rev Iberoam Micol (2009) 1.21
One fungus, one name: defining the genus Fusarium in a scientifically robust way that preserves longstanding use. Phytopathology (2013) 1.19
Posaconazole combined with amphotericin B, an effective therapy for a murine disseminated infection caused by Rhizopus oryzae. Antimicrob Agents Chemother (2008) 1.18
Adiaspiromycosis causing respiratory failure and a review of human infections due to Emmonsia and Chrysosporium spp. J Clin Microbiol (2012) 1.18
Correlation between in vitro susceptibility of Scedosporium apiospermum to voriconazole and in vivo outcome of scedosporiosis in guinea pigs. Antimicrob Agents Chemother (2004) 1.16
Whole genome sequence typing to investigate the Apophysomyces outbreak following a tornado in Joplin, Missouri, 2011. PLoS One (2012) 1.16
Efficacy of voriconazole in treatment of systemic scedosporiosis in neutropenic mice. Antimicrob Agents Chemother (2003) 1.16
Presence of Arcobacter spp. in environmental waters correlates with high levels of fecal pollution. Environ Microbiol (2008) 1.15
Cuff-leak test for the diagnosis of upper airway obstruction in adults: a systematic review and meta-analysis. Intensive Care Med (2009) 1.15
Trichosporon mycotoxinivorans, a novel respiratory pathogen in patients with cystic fibrosis. J Clin Microbiol (2009) 1.14
Prevalence of Arcobacter in meat and shellfish. J Food Prot (2009) 1.14
Correlation of antifungal susceptibility and molecular type within the Cryptococcus neoformans/C. gattii species complex. Med Mycol (2011) 1.13
Actinomucor elegans var. kuwaitiensis isolated from the wound of a diabetic patient. Antonie Van Leeuwenhoek (2008) 1.12
In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi. Med Mycol (2005) 1.11
Scopulariopsis, a poorly known opportunistic fungus: spectrum of species in clinical samples and in vitro responses to antifungal drugs. J Clin Microbiol (2013) 1.11
Fungal endophthalmitis caused by Aspergillus ustus in a patient following cataract surgery. Med Mycol (2006) 1.10
Stabilization of a full-length infectious cDNA clone of transmissible gastroenteritis coronavirus by insertion of an intron. J Virol (2002) 1.10
Saksenaea vasiformis infections: case report and literature review. Mycopathologia (2006) 1.09
Genus Hamigera, six new species and multilocus DNA sequence based phylogeny. Mycologia (2010) 1.08
In vitro antifungal susceptibilities of Sporothrix schenckii in two growth phases. Antimicrob Agents Chemother (2005) 1.07
Role of the white collar 1 photoreceptor in carotenogenesis, UV resistance, hydrophobicity, and virulence of Fusarium oxysporum. Eukaryot Cell (2008) 1.06
HapX-mediated iron homeostasis is essential for rhizosphere competence and virulence of the soilborne pathogen Fusarium oxysporum. Plant Cell (2012) 1.06
Phosphorylation of human respiratory syncytial virus P protein at threonine 108 controls its interaction with the M2-1 protein in the viral RNA polymerase complex. J Gen Virol (2006) 1.06
The velvet complex governs mycotoxin production and virulence of Fusarium oxysporum on plant and mammalian hosts. Mol Microbiol (2012) 1.06
Two new species of Mucor from clinical samples. Med Mycol (2010) 1.05
Trends in sample preparation for classical and second generation proteomics. J Chromatogr A (2007) 1.05
Genotyping of Scedosporium species: a review of molecular approaches. Med Mycol (2008) 1.05
Efficacy of micafungin in combination with other drugs in a murine model of disseminated trichosporonosis. Antimicrob Agents Chemother (2005) 1.05
Effects of double and triple combinations of antifungal drugs in a murine model of disseminated infection by Scedosporium prolificans. Antimicrob Agents Chemother (2009) 1.05
Genotyping of 44 isolates of Fusarium solani, the main agent of fungal keratitis in Brazil. J Clin Microbiol (2004) 1.04
Interaction of granulocyte colony-stimulating factor and high doses of liposomal amphotericin B in the treatment of systemic murine scedosporiosis. Diagn Microbiol Infect Dis (2004) 1.04
General statistical framework for quantitative proteomics by stable isotope labeling. J Proteome Res (2014) 1.04
Nitric oxide increases cardiac IK1 by nitrosylation of cysteine 76 of Kir2.1 channels. Circ Res (2009) 1.03
Third target of rapamycin complex negatively regulates development of quiescence in Trypanosoma brucei. Proc Natl Acad Sci U S A (2012) 1.03
In vitro interactions of licensed and novel antifungal drugs against Fusarium spp. Diagn Microbiol Infect Dis (2004) 1.02
Potential virulence and antimicrobial susceptibility of Aeromonas popoffii recovered from freshwater and seawater. FEMS Immunol Med Microbiol (2002) 1.02